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Abstract 
Resistance in nucleoside / nucleotide analogue (NA) therapy has always been a 
challenge in the management of chronic hepatitis B (CHB). Initially developed for the 
treatment of HIV infection, early in vitro and clinical observational studies had shown 
tenofovir disoproxil fumarate (TDF) to be also active against CHB. Recent data from 
various multicenter phase 3 and 4 clinical trials have confirmed TDF being able to 
achieve a high viral suppression in both NA-naïve and -experienced CHB patients. 
There are also emerging data on the efficacy of TDF in decompensated CHB. Although 
there are in vitro studies identifying certain mutation loci associated with a reduced 
susceptibility to TDF, there have so far been no reports of virologic resistance to TDF in 
clinical studies. TDF has a favorable safety profile, although more long-term data would 
be needed. In conclusion, TDF has the makings of an “ideal” first-line drug for the 
treatment of CHB. 
Introduction 
 Chronic hepatitis B (CHB) infection constitutes a global health burden, with 400 
million patients infected with the hepatitis B virus (HBV) (1), and an estimated 600,000 
people dying annually from complications of CHB (2). The last two decades have seen 
the introduction of various nucleoside / nucleotide analogues (NA) (3-7). There is 
increasing medical evidence supporting long-term NA therapy in order to maintain a 
permanent virologic suppression (8), since this could result in histologic improvement 
with reversal of fibrosis (9) and reduce the incidence of cirrhotic complications and 
hepatocellular carcinoma (HCC) (10, 11). 
 The prerequisites for long-term therapy include a simple dosing regimen to 
ensure drug compliance, satisfactory tolerability, minimal toxicity, favorable potency, 
and minimal drug resistance. Drug resistance is an important issue in NA therapy, 
especially with lamivudine, adefovir and telbivudine (12). Resistance to lamivudine can 
be up to 67% and more than 75% after 4 and 5 years of therapy respectively (11, 13). 
The cumulative resistance rate of telbivudine is 34% after 3 years (14). Both lamivudine 
and telbivudine have a low genetic barrier to resistance, with only one mutation at the 
rtM204V/I loci required. The acyclic structure of adefovir has a high molecular flexibility, 
resulting in effective drug action even when there are minor alterations in the binding 
pocket as a result of viral mutations (15). Despite this molecular advantage, the 
resistance rate of adefovir is still 22% after 2 years of therapy (16), with mutations at the 
rtA181T and rtN236T loci.  
 An ideal NA would need to have a durable antiviral potency and also a high 
genetic barrier of resistance. Entecavir was the first drug with favorable properties, with 
only a resistance rate of 1.2% after 5 years of therapy in treatment-naïve CHB patients 
(17, 18). However the results in lamivudine-resistant patients are suboptimal, with a 
resistance rate of 51% after 5 years of therapy (17, 19). This review discusses another 
potent NA recently available for CHB treatment: tenofovir disoproxil fumarate (TDF). 
 
Early observational studies 
 TDF is an orally bioavailable prodrug of tenofovir (20), which belongs to a class 
of drugs known as acyclic nucleoside phosphonates (21), known for their potent antiviral 
activity against both DNA and RNA viruses through direct binding with the viral 
polymerases. TDF was first approved by the US Food and Drug Administration (FDA) 
for the treatment of human immunodeficiency virus (HIV) infection in 2001, and has 
since become the cornerstone for anti-HIV combination treatment regimens. TDF is also 
active against HBV, with in vitro studies showing potent antiviral activity against both 
wild-type and lamivudine-resistant HBV(22). Tenofovir is converted to its active form 
through a two-step phosphorylation, and terminates chain elongation catalyzed by the 
HBV DNA polymerase. 
 The initial clinical evidence of TDF in the treatment of CHB arose from HIV-HBV 
co-infected individuals. In 2002, van Bommel et al treated 5 lamivudine-resistant 
patients with HBV and HIV co-infection with TDF 300 mg daily, resulting in a 4.5 log 
reduction in HBV DNA by week 24 (23).  Two similar studies by Ristig et al (24) and 
Benhamou et a l(25) in 6 and 10 co-infected individuals respectively also had similar 
findings, with serum HBV DNA decreasing by 4.3 logs and 3.8 logs respectively at week 
24. The first comparative study in 12 co-infected individuals also found TDF achieving 
better viral suppression when compared to placebo (26). TDF was also found to achieve 
potent viral suppression in a small study of CHB patients with no HIV co-infection (27), 
as well as in lamivudine-resistant patients following liver transplantation (28). 
 The initial success of TDF led to comparative studies with adefovir dipivoxil, also 
an acyclic nucleoside phosphatase, which was approved by the US FDA for the 
treatment of CHB infection in 2002. The main use of adefovir was as “rescue” therapy in 
lamivudine resistance (29, 30), but its usage is hindered by the increased frequency of 
adefovir resistance mutations when compared to NA-naïve patients (31). In the first 
study comparing TDF and adefovir (32), 53 lamivudine-resistant patients were treated 
with TDF 300 mg daily or adefovir 10 mg daily for up to 130 weeks.  The majority of 
patients had HIV co-infection. TDF was shown to achieve a faster HBV DNA reduction 
by week 4 when compared to adefovir, with the HBV DNA reduction becoming 
significantly better than adefovir by week 12. All patients on TDF achieved undetectable 
HBV DNA (less than 69 IU/mL) at week 48, compared to 44% of patients on adefovir. 
There was no evidence of phenotypic viral resistance to TDF up to week 130. Despite 
the similar molecular structure of TDF and adefovir, TDF was also effective in patients 
with sub-optimal virologic response to adefovir (33). 
 
 Clinical trials of tenofovir disoproxil fumarate in chronic hepatitis B 
From the above observational studies, based on its antiviral potency, minimal 
resistance and effectiveness in lamivudine-resistant patients, TDF has the potential to 
become the “ideal” drug for CHB. This had led to the commencement of different trials 
in both treatment-naïve and NA-experienced CHB patients (Table 1). 
 Marcellin and Heathcote et al conducted the first randomized double-blind study 
concerning TDF, with both HBeAg-positive (study 103) and -negative (study 102) 
patients with compensated liver disease randomly assigned to receive either TDF 
(n=426) or adefovir (n=215) for 48 weeks (34). A small proportion of patients were 
previously treated with lamivudine, emtricitabine or interferon. The primary endpoint was 
a serum HBV DNA level of less than 69 IU/mL (or 400 copies/mL). By weeks 4 to 12, 
there was already an obvious difference in viral suppression between the two treatment 
groups. By week 48, significantly more patients on TDF achieved HBV DNA 
undetectability (76% for HBeAg-positive, 93% for HBeAg-negative) when compared to 
adefovir (13% and 63% respectively). Three percent of HBeAg-positive patients on TDF 
achieved hepatitis B surface antigen (HBsAg) seroclearance, while histologic 
improvements were similar in both treatment groups. Tenofovir produced similar viral 
suppression in patients with prior lamivudine treatment.  
  Patients from the above studies, irrespective of their therapeutic response, were 
then enrolled in a follow-up study to receive open-label TDF for 7 years (35). Patients 
from both groups with detectable serum HBV DNA at week 72 were eligible to receive 
tenofovir together with emtricitabine at the discretion of the investigators. The primary 
endpoints were the serologic and virologic outcomes and the resistance profile at week 
144 (n=542). Up to 72% and 87% of HBeAg-positive and -negative patients respectively 
achieved undetectable HBV DNA (less than 69 IU/mL) by week 144. Patients who were 
originally on adefovir and subsequently switched to TDF at week 48 also had similar 
outcomes. No resistance to tenofovir was detected. A cumulative 8% of HBeAg-positive 
patients (the majority being genotype A and D) achieved HBsAg seroclearance, 
although there were no cases of HBsAg loss in HBeAg-negative patients. When the 
same patient cohort was followed up to week 192, rates of undetectable HBV DNA were 
77% and 86% in HBeAg-positive and -negative patients respectively. HBsAg 
seroclearance rate among HBeAg-positive patients increased to 10%, with 7.5% 
seroconverting to serum antibody to HBsAg (anti-HBs) (36, 37). In a sub-group analysis 
of patients with high baseline viral load (more than 8.3 log IU/mL), more than 95% 
achieved undetectable HBV DNA and 15.2% of HBeAg-positive patients achieved 
HBsAg seroclearance (38) at week 192. Another subgroups analysis of 198 Asian CHB 
patients also found 79% (74% HBeAg-positive, 84% HBeAg-negative) achieving HBV 
DNA undetetectability at week 192, although there were no Asian patients achieving 
HBsAg seroclearance (39). Of the 51 patients eligible for receiving combination of TDF 
and emtricitabine, 34 had combination therapy while 17 remained on TDF monotherapy. 
There was no difference in viral suppression between those receiving combination 
therapy and those whom continued to receive TDF monotherapy up to year 3 (35). 
 TDF is also effective in patients with prior exposure to different NAs. A 
randomized double-blind study by Berg et al. in Europe (40) recruited patients with an 
incomplete virologic response to adefovir (n=105) with 31 having proven adefovir 
resistance mutations and 25 having lamivudine resistance mutations. They were 
randomly assigned to either TDF or TDF plus emtricitabine. At 48 weeks, 81% of 
patients in both treatment groups had HBV DNA levels of less than 69 IU/mL. A 
continued follow-up of the same patient cohort showed similar viral suppression (86%) 
up to week 168 (41).  Another prospective study by Patterson et al in Australia (42) 
enrolled 60 patients with incomplete virologic response to both lamivudine and adefovir. 
After 96 weeks of TDF or combination TDF and lamivudine, 64% of patients achieved 
HBV DNA levels of less than 15 IU/mL. Viral suppression was similar regardless of the 
addition of lamivudine. Both the European and Australian studies found treatment 
response to be independent of baseline mutations. An preliminary Italian study also 
showed similar findings (43). 
 However, the above findings were not entirely reproduced in a retrospective 
multicenter study from Germany (44), with 131 NA-experienced patients having 
previous treatment failure with lamivudine, adefovir, combination lamivudine and 
adefovir or entecavir. After a mean treatment duration of 23 months, 79% achieved a 
HBV DNA level below 69 IU/mL. HBsAg seroclearance occurred in 3% of patients. 
Unlike the previous three studies, the presence of adefovir mutations impaired TDF 
efficacy when compared to the presence of lamivudine mutations (52% versus 100% 
respectively achieving viral suppression). The outcome of adefovir-resistant patients in 
different trials is depicted in Table 2. For all 4 studies, the number of patients with 
proven genotypic adefovir resistance is actually small. In addition, different methods of 
resistance methods were used. Two of the four studies (42, 44) only used direct 
sequencing for resistance detection, a method which could only detect mutations if 
there are at least 20-30% of mutants circulating in the total viral population (45). The 
other 2 studies (40, 43) used a line probe assay (LiPA), which is able to detect 
mutations constituting 5% of the total viral population (46). Further studies with a larger 
study population are needed to determine the efficacy of TDF in adefovir-resistant 
patients. 
  
Tenofovir in decompensated chronic hepatitis B 
 The use of NAs in decompensated CHB had previously shown mixed results. 
Lamivudine was able to improve liver function in decompensated CHB (47), but 
evidence on its effect in improving survival has been mixed (48, 49). The use of adefovir 
in decompensated CHB also improved liver function significantly, however 14% of 
patients died within the first year and 33% still required liver transplantation for long-
term survival (50). Entecavir in decompensated CHB achieved an 87% to 91% 1-year 
patient survival (51, 52). However there were reports of 5 cases of lactic acidosis 
according to a study with limited number of patients (53) The same center subsequently 
describe similar cases of lactic acidosis with other NAs There was also a possible 
increase in short-term mortality when used in acute exacerbation of CHB in a 
retrospective study comparing entecavir and lamivudine in 36 and 117 patients 
respectively (54). 
 A recent study compared TDF (n=45), emtricitabine / TDF (n=45) and entecavir 
(n=22) in patients with decompensated CHB for 48 weeks (52). All 3 treatment arms 
had comparable biochemical and virologic improvements. Patients on TDF or 
emtricitabine / TDF were more likely to achieve HBeAg loss. There were no cases of 
lactic acidosis reported for any treatment group. 
 
Tenofovir in acute on chronic liver failure 
 A  recent prospective study randomized patients diagnosed with acute-on-
chronic liver failure due to CHB to either TDF (n=14) or placebo (n=13) (55). Patients 
were followed up for 3 months, with no liver transplantation offered due to its 
unavailability. Fifty-seven percent of patients on TDF survived compared to 15% of the 
placebo patients. One patient on TDF developed HBsAg seroclearance. Patients on 
TDF also showed marked virologic and biochemical improvements, with a 2 log HBV 
DNA reduction within 2 weeks independently predicting survival. Despite its small 
sample size, the authors concluded that responders to TDF could be identified within 2 
weeks, thus optimizing patient selection for liver transplantation. Prospective studies on 
a larger scale are needed to confirm this finding. 
 
Tenofovir in solid organ transplant recipients 
 The use of TDF in solid organ transplant recipients has not been extensively 
studied, with most studies to date focusing on lamivudine. 
 A recent small study on 7 transplant recipients with prior suboptimal response to 
other NAs found TDF to be both efficacious and safe (56). Another small study followed 
up 8 patients with HBV recurrence after liver transplantation. Four patients had 
detectable viremia despite entecavir, and eventual viral suppression was achieved with 
the addition of TDF (57). While more large-scale studies are required to determine  
efficacy and safety of TDF in this special group of patients, it would be reasonable to 
anticipate an optimal virologic response and low rates of resistance. 
 
Resistance profile of tenofovir 
 To date, there are no reports of any virologic resistance to TDF among patients 
with CHB monoinfection. 
A phenotypic analysis with recombinant HBV was performed using serum 
derived from studies 102 and 103 (34, 35). The majority of these patients were NA-
naïve, and baseline genotypic mutations were only found in 1.1% of patients (all 
lamivudine-related rtM204V/I with or without rtL180M). Serum was chosen from patients 
who developed virologic breakthrough, although virologic breakthroughs were 
infrequent and found to be mostly associated with drug non-compliance. No patients 
developed amino acid substitutions associated with resistance to TDF up to week 144 
(58).  
 The first study to suggest a mutation loci associated with TDF resistance was 
based on 43 CHB patients with HIV co-infection (59). The rtA194T substitution found in 
2 patients was found to be associated with reduced susceptibility to TDF in vitro when 
the lamivudine mutations of rtM204V and rtL180M were present. Nevertheless, further 
studies concerning the rtA194T mutation showed mixed results. A subsequent in vitro 
study failed to reproduce the results of Sheldon et al (60). Another study using 
replicated HBV plasmid harboring rtA194T alone or with lamivudine-associated mutants 
found the rtA194T mutation to be associated with partial resistance to TDF; however, 
the effect on resistance is negated when the mutations occur together with precore or 
basic core promoter substitutions (61). 
The clinical impact of the rtA194T mutation is still unknown. A preliminary clinical 
study followed up 10 CHB patients with the rtA194T mutation present before 
commencing on TDF. After receiving either TDF monotherapy or in combination with 
either lamivudine or emtricitabine for 1.5 years, all patients had at least 3 log reduction 
in DNA after 12 weeks, and 9 patients achieved HBV DNA levels of less than 100 IU/mL 
at their last follow-up (62).  
In vitro studies had also found the adefovir-associated mutations rtA181T and 
rtN236T to be associated with reduced susceptibility to TDF (63, 64). As mentioned 
previously, clinical studies on the efficacy of TDF in adefovir-resistant patients showed 
mixed results (40, 42-44). 
It is possible that TDF results in rapid viral suppression, thus preventing resistant 
strains with reduced replicative capacity from taking over the majority of the viral 
population, making the rtA194T, rtA181T or the rtN236T mutations clinically irrelevant. 
More long-term studies with larger cohort of patients on TDF harboring the above 
mutations would be needed before definitive conclusions can be drawn. 
 
Cost utility analysis of tenofovir 
 Data on the cost-effectiveness of TDF is emerging. A recent study from the 
United Kingdom investigated this issue, using a Markov model to compare TDF with 
lamivudine, adefovir and entecavir. First-line TDF was found to be the most cost-
effective treatment for patients with CHB, costing £ 19,084 per quality-adjusted life-year 
gained compared with the next best alternative (65). Another study compared the 12-
month treatment outcomes of the five NAs and pegylated interferon in various 
randomized control trials using a Bayesian mixed treatment comparison model. TDF 
was found to be most cost-effective in HBeAg-negative disease (66). Given its limited 
availability in Asia, similar cost utility analysis of TDF in Asia is lacking, although a Hong 
Kong study on the cost-effectiveness of other NAs found TDF to be the most cost-
effective if TDF was priced similarly to telbivudine (67). 
 
   
Safety 
 An understanding of the safety profile of TDF is essential, especially when NA 
therapy is likely to be long-term in order to achieve permanent viral suppression. 
Tenofovir is primarily excreted by the kidneys, and the most important safety concern of 
TDF would be its association with renal dysfunction. The majority of cases with TDF-
associated renal impairment were reported from the HIV population. Although less 
commonly seen when compared to adefovir therapy, prolonged treatment with TDF is 
associated with renal proximal tubular dysfunction (68-70) and hypophosphatemia, the 
latter secondary to reduced phosphate reabsorption and excessive loss of urinary 
phosphates (71-73). Fanconi syndrome and acute renal failure have also been reported 
(74, 75), although the nephrotoxicity is usually reversible when therapy is stopped. TDF 
is associated with a 4% decline in glomerular filtration rate (GFR) in HIV patients over 
one year (76) and a decline of 9.8 mL/min/1.37 m2 up to 5 years(77), although given the 
differences in disease nature, such data might not be directly applicable in CHB. 
 Safety data of long-term TDF in CHB is emerging. In patients with HIV co-
infection taking TDF, GFR declined by 22.19 ml/min/1.73 mm2 from baseline over a 
median follow-up period of 251 weeks (78). However, clinical trials of TDF in CHB 
monoinfection mentioned previously did not detect any significant changes in creatinine 
levels or creatinine clearance up to 144 weeks (35, 42, 44). An preliminary Italian study 
followed 737 CHB patients on TDF for a median period of 16 months, of which 524 had 
prior exposure to other NAs. Less than 1% of patients had an increase in serum 
creatinine of more than 44 umol/L (or 0.5 mg/dL). In terms of tubular function, 37% 
patients had a significant decrease in urinary phosphate reabsorption, of which the 
majority had prior exposure to adefovir. The authors concluded that TDF had a 
favorable safety profile, with only a few patients (mainly NA-experienced) showing a 
mild degree of renal dysfunction (79). TDF usage in decompensated liver disease is of 
special concern, especially since many such patients have concurrent renal impairment. 
In a study on patients with decompensated CHB, only 7.8% had an increase in serum 
creatinine of more than 44 umol/L after 48 weeks of TDF (52), which was not 
significantly different from the 4.5% observed with entecavir in the same study.  
 Dosage adjustments are required for patients with a creatinine clearance of less 
than 50 ml/min. TDF is taken at 300mg every 48 hours for patients with a creatinine 
clearance of 30 to 49 ml/min, and every 72 to 96 hours for those with a creatinine 
clearance of 10 to 29 ml/min. Patients on hemodialysis should take TDF every 7 days 
following dialysis. 
 Concerning non-renal side effects of TDF, there had been some concerns of TDF 
being associated with a low bone mineral density and fat redistribution (80, 81). 
However, a recent study of HIV-infected individuals with 10 years of follow-up did not 
find any significant changes in both bone mineral density and limb fat (82). More safety 
data is needed concerning the significance of non-renal side effects of TDF in CHB. 
 TDF is labeled by the US FDA as a category “B” pregnancy drug. Animal 
reproduction studies using doses up to 19 times the human dose revealed no evidence 
of impaired fertility of harm to the fetus. There are currently no adequate well-controlled 
studies of TDF in pregnant woman. However in a follow-up of 3695 HIV-infected 
mothers treated with TDF or lamivudine, the incidence of congenital fetal abnormalities 
was 2.3% and 2.7% respectively, which was not different from the incidence of 
congenital abnormalities in NA-naïve mothers(83). Maternal bioavailability may be 
decreased in the third trimester. Concerning lactation, animal studies have 
demonstrated that TDF is secreted in milk, and breastfeeding is not advised for mothers 
taking TDF (84). 
 
Future directions and conclusions 
 One interesting phenomenon with TDF is the relatively high HBsAg 
seroclearance noted in HBeAg-positive CHB with genotypes A and D, with a cumulative 
rate of 10% after 192 weeks of therapy (36). Given the low incidence of spontaneous 
and NA-induced HBsAg seroclearance (18, 85-87), the possibility of HBsAg 
seroclearance as a treatment endpoint is finally potentially achievable. Despite this 
optimism, preliminary studies of TDF in Asians (majority being genotypes B and C) did 
not achieve HBsAg seroclearance (39). This could be related to the different 
immunology of HBV infection in Asians compared to Caucasians, with Asians acquiring 
the infection at the early stages of life (8). Further long-term studies in different ethnic 
groups are needed to address this issue. Additional data of the efficacy of TDF in 
adefovir-resistant cases and long-term safety profile would also be needed. 
 In conclusion, with its potent viral suppression, favorable resistance profile, and 
superior efficacy in lamivudine rescue therapy when compared to adefovir, TDF is 
perhaps the “ideal” first-line drug in the treatment of CHB. 
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